GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets

European Journal of Neuroscience

Volumn 13, Issue 3, 2001, Pages 597-608

  Iravani, M M ^a   Costa, S ^a   Jackson, M J ^a   Tel, B C ^a   Cannizzaro, C ^a   Pearce, R K B ^a   Jenner, P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dyskinesia; Glial cell line derived neurotrophic factor; L DOPA; Marmoset; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; MAZINDOL; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC TRANSMISSION; DYSKINESIA; MARMOSET; MOTOR DYSFUNCTION; MUSCULOSKELETAL SYSTEM; NERVE CELL DEGENERATION; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANIMALS; ANTIPARKINSON AGENTS; BODY WEIGHT; CALLITHRIX; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; DYSKINESIA, DRUG-INDUCED; ENKEPHALINS; FEMALE; GENE EXPRESSION; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; LEVODOPA; LOCOMOTION; MALE; MAZINDOL; MPTP POISONING; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PROTEIN PRECURSORS; RECOVERY OF FUNCTION; RNA, MESSENGER; SUBSTANTIA NIGRA; TACHYKININS; TRITIUM; TYROSINE 3-MONOOXYGENASE;

EID: 0035131350     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9568.2001.01408.x     Document Type: Article

References (54)

1. Pathophysiology of L-dopa-induced abnormal involuntary movements
2. Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkey
3. 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line- derived neurotrophic factor
4. Aetiology of Parkinson's disease
5. Molecular basis of levodopa-induced dyskinesias
6. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin and glutamic acid decarboxylase mRNA
7. Dopaminergic neurons protected from degeneration by GDNF gene therapy
8. GDNT improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro
9. GDNF concentration dependently improves disability and motor activity in MPTP-treated common marmosets
10. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias
11. Ageing and Parkinson's disease: Substantia nigra regional selectivity
12. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys
13. Functional recovery in parkinsonian monkeys treated with GDNF
14. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons
15. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: In situ hybridization histochemical analysis
16. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys
17. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset
18. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: An autoradiographic study
19. Glial-derived neurotrophic factor (GDNF) induced morphological differentiation of an immortalized monoclonal hybrid dopaminergic cell line of mesencephalic neuronal origin
20. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo
21. Glial-cell-line-derived neurotrophic factor enhances biosynthesis of substance P in striatal neurons in vitro
22. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity
23. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates
24. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset
25. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP
26. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo
27. GDNF protection against 6-OHDA: Time dependence and requirement for protein synthesis
28. 125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection
29. Glial cell line-derived neurotropbic factor: Distribution and pharmacology in the rat following a bolus intraventricular injection
30. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: Comparison of intraventricular and intranigral delivery
31. Biology of glial cell line-derived neurotrophic factor (GDNF): Implications for the use of GDNF to treat Parkinson's disease
32. Success and problems of long-term levodopa therapy in Parkinson's disease
33. Intranigral or intrastriatal injections of GDNF: Effects on monoamine levels and behavior in rats
34. Rate of cell death in parkinsonism indicates active neuropathological process
35. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys
36. A review of some aspects of the pharmacology of levodopa
37. Motor complications associated with chronic levodopa therapy in Parkinson's disease
38. Preventing levodopa-induced dyskinesias
39. Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP-treated common marmoset
40. Chronic L-DOPA administration induces dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus)
41. Presynaptic recording of quanta from midbrain dopamine neurons and modulation of the quantal size
42. Medical treatment of levodopa-induced dyskinesias
43. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle
44. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion
45. Effects of combined BDNF and GDNF treatment on cultured dopaminergic midbrain neurons
46. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo
47. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
48. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests atrophic role in the adult
49. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine
50. Glial cell line-derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: Dose-response comparison to nerve growth factor and brain-derived neurotrophic factor
51. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease
52. Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat
53. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys